2,6-Dimethyl-4-(3'-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylic acid 3-β-(N-benzyl-N-methylamino)ethyl ester 5-ethyl ester | 55985-39-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: 2,6-Dimethyl-4-(3'-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylic acid 3-β-(N-benzyl-N-methylamino)ethyl ester 5-ethyl ester
• 英文别名: 5-O-[2-[benzyl(methyl)amino]ethyl] 3-O-ethyl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate
• CAS: 55985-39-2
• 化学式: C₂₇H₃₁N₃O₆
• 分子量: 493.56
• InChiKey: HWWKDKHFBKOFGX-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.2
• 重原子数：
  36
• 可旋转键数：
  11
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  114
• 氢给体数：
  1
• 氢受体数：
  8

文献信息

• [EN] DIHYDROPYRIDINE COMPOUNDS HAVING SIMULTANEOUS ABILITY TO BLOCK L-TYPE CALCIUM CHANNELS AND TO INHIBIT PHOSPHODIESTERASE TYPE 3 ACTIVITY<br/>[FR] COMPOSES DE DIHYDROPYRIDINE PRESENTANT A LA FOIS LA CAPACITE DE BLOQUER DES CANAUX CALCIQUES DE TYPE L ET LA CAPACITE D'INHIBER L'ACTIVITE DE TYPE 3 DE LA PHOSPHODIESTERASE
  申请人：ARTESIAN THERAPEUTICS INC

  公开号：WO2004033444A1

  公开（公告）日：2004-04-22

  The present invention provides compounds that possess inhibitory activity against PDE-3 and L-type calcium channels. The present invention further provides pharmaceutical compositions comprising such compounds and methods of using such compounds for treating cardiovascular disease, stroke, epilepsy, ophthalmic disorder or migraine.

  本发明提供了具有对PDE-3和L型钙通道具有抑制活性的化合物。本发明还提供了包含这些化合物的药物组合物以及使用这些化合物治疗心血管疾病、中风、癫痫、眼科疾病或偏头痛的方法。
• Compounds having simultaneous ability to block L-type calcium channels and to inhibit phosphodiesterase type 3 activity
  申请人：Hamilton S. Gregory

  公开号：US20070066619A1

  公开（公告）日：2007-03-22

  The present invention provides compounds that possess inhibitory activity against PDE-3 and L-type calcium channels. The present invention further provides pharmaceutical compositions comprising such compounds and methods of using such compounds for treating cardiovascular disease, stroke, epilepsy, ophthalmic disorder or migraine.

  本发明提供了具有对 PDE-3 和 L 型钙通道抑制活性的化合物。本发明还提供了包含这些化合物的药物组合物以及使用这些化合物治疗心血管疾病、中风、癫痫、眼科疾病或偏头痛的方法。
• US3985758A
  申请人：——

  公开号：US3985758A

  公开（公告）日：1976-10-12
• [EN] METHODS AND COMPOSITIONS FOR THE TREATMENT OF PULMONARY HYPERTENSION USING A COMBINATION OF A CALCIUM CHANNEL BLOCKER AND A PHOSPHODIESTERASE INHIBITOR<br/>[FR] MÉTHODES ET COMPOSITIONS POUR LE TRAITEMENT D'HYPERTENSION PULMONAIRE UTILISANT UNE COMBINAISON D'UN AGENT BLOQUANT DE CANAL CALCIUM ET UN INHIBITEUR DE PHOSPHODIESTÉRASE
  申请人：ARTESIAN THERAPEUTICS INC

  公开号：WO2008019106A1

  公开（公告）日：2008-02-14

  [EN] The present invention provides novel methods for the treatment of pulmonary hypertension. In particular, the present invention includes methods of treating pulmonary hypertension using a combination of a calcium channel blocker and a phosphodiesterase inhibitor, as well as pharmaceutical compositions comprising a calcium channel blocker and a phosphodiesterase inhibitor, including, e.g., admixtures suitable for delivery by inhalation.
  [FR] La présente invention a pour objet des méthodes nouvelles pour traiter une hypertension pulmonaire. En particulier, la présente invention comprend des méthodes pour traiter une hypertension pulmonaire qui utilise en combinaison un agent bloquant de canal calcium et un inhibiteur de la phosphodiestérase, ainsi que des compositions pharmaceutiques qui comprennent un agent bloquant de canal calcium et un inhibiteur de la phosphodiestérase, y compris, par exemple, des mélanges appropriés à une administration par inhalation.
• [EN] COMPOUDS AND USES AS L-TYPE CALCIUM CHANNEL BLOCKER AND/OR ACETYLCHOLINESTERASE INHIBITOR THEREOF<br/>[FR] COMPOSÉS ET LEURS UTILISATIONS EN TANT QU'AGENTS BLOQUANTS DU CANAL CALCIUM DE TYPE P ET/OU EN TANT QU'INHIBITEURS DE L'ACÉTYLCHOLINESTÉRASE
  申请人：JIANGSU SIMCERE PHARMACEUTICAL R & D CO LTD

  公开号：WO2012065527A1

  公开（公告）日：2012-05-24

  Disclosed in this invention are compounds and the uses as L-type calcium channel blocker and/or acetylcholinesterase inhibitor thereof. The uses of said compounds in the manufactures of a medicament for the treatment of cardiovascular diseases, apoplexy or senile dementia are also disclosed in the present invention.